CGT manufacturers need to get better at gathering process data to move manufacturing into the digital age according to a new study [Reptile8488/Getty Images]

Cell and gene therapy (CGT) production will only enter the digital age when the industry gets better at gathering process data, according to researchers, who say closed systems and advanced monitoring technologies will be vital.

Unlike in pharma, the fourth industrial revolution has not reached the CGT sector, according to Aleksander Szarzynski, a researcher at the Vienna University of Technology and co-author of a new study looking at cell and gene therapy production.